Abilify ODT 15 mg (Aripiprazole)

Adult dose

For adult schizophrenia, the recommended initial dosage is 10 mg or 15 mg once daily, regardless of meals. Dosing may be adjusted within the range of 10-30 mg daily; however, increases should not occur within 2 weeks. The maintenance therapy consists of 15 mg daily for more than 3 months. For adult bipolar disorder, the recommended initial dose is 15 mg once daily, and may be increased to 30 mg daily based on clinical response.

Child dose

Recommended dosage for adolescents with schizophrenia (aged 13-17 years) is 10 mg once daily, regardless of meals. Initial dose is 2 mg once daily, followed by 5 mg after 2 days, and 10 mg after another 2 days, then further increase to 5 mg as needed.

This medication may increase the risk of suicidal thoughts or behaviors in children, adolescents, and young adults with depression or psychiatric disorders; therefore, careful consultation with a doctor before use is essential. During the initial treatment phase, the patient's condition may worsen or unusual behaviors may appear, so family members and caregivers should observe the patient carefully and notify the healthcare provider immediately if any atypical signs are observed. When administering this medication to patients with bipolar disorder, it is important to verify the presence of mania or mixed episodes prior to treatment. Neuroleptic malignant syndrome, which can be fatal, may occur; therefore, if symptoms such as fever, muscle rigidity, and changes in mental status occur, medical attention should be sought immediately. Long-term use may result in irreversible abnormal movement symptoms, so it should be used at the minimum dosage and for the shortest duration possible, with medical consultation required if symptoms arise. Use of this medication in elderly patients with dementia may increase the risk of cerebrovascular accidents such as strokes and mortality; thus, it is advisable not to administer it to patients in this age group. Since this medication can affect blood sugar control, diabetic patients should monitor their blood sugar levels regularly and be vigilant for symptoms of hyperglycemia. There is a risk of venous thromboembolism; therefore, patients with thrombotic risk factors should be monitored carefully before and during administration. This medication contains aspartame, an artificial sweetener, and should not be taken by patients with phenylketonuria. Symptoms such as orthostatic hypotension, seizures, and drowsiness may occur, so caution is needed when driving or operating hazardous machinery. Aspiration pneumonia and dysphagia risks may be present, so particularly elderly patients should be monitored closely. Possible adverse reactions during the use of this medication include nausea, vomiting, constipation, headache, dizziness, insomnia, anxiety, drowsiness, weight gain, etc. If severe or sudden atypical symptoms occur during treatment, immediate consultation with a physician is necessary, along with regular examinations and monitoring.

Serious side effects

Hives, severe swelling, chest tightness, difficulty breathing, cold sweat, paleness, severe rash with high fever, blisters, skin peeling, pain in the mucous membranes of the mouth/eyes, shortness of breath or difficulty breathing, asthma attack, respiratory abnormalities accompanied by cough and fever, yellowing of skin or eyes (jaundice), extreme lethargy, sudden and severe headache, thunderclap headache, seizures, confusion of consciousness, visual disturbances, paralysis, significant decrease in urine output

Mild side effects

• Nausea
• vomiting
• constipation
• headache
• dizziness
• akathisia
• anxiety
• insomnia
• restlessness
• drowsiness

This medication may be sensitive to air and moisture; therefore, it should be stored in a tightly sealed container. It is advisable to maintain the storage temperature between 1°C and 30°C room temperature to preserve the medication's efficacy for a longer period.

Appearance

Round tablets with yellow spots (imprint A641, 15)

Package unit

30 tablets (10 tablets/PTP X 3)